These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38276934)

  • 1. Angiotensin Receptor Neprilysin Inhibition Across Ejection Fraction and Acuity Spectra in Heart Failure.
    Myhre PL; Lam CSP
    JACC Heart Fail; 2024 Mar; 12(3):583-587. PubMed ID: 38276934
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some.
    Ventura HO; Lavie CJ; Mehra MR
    J Am Coll Cardiol; 2023 Jul; 82(1):13-15. PubMed ID: 37220861
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF.
    Vaduganathan M; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2020 Sep; 22(9):1525-1530. PubMed ID: 32741093
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.
    Jia R; Ji Y; Sun D
    Biomed Pharmacother; 2022 Nov; 155():113701. PubMed ID: 36116249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Vaduganathan M; Desai AS
    Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 11. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O; Tacheny T; Solomon SD
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.